Meningococcal Vaccines Market Share: Competitive Landscape Analysis With Forecast by 2027
Market Highlights
According to Market Research
Future (MRFR) analysis, the Meningococcal
Vaccines Market Share 2020 can thrive at a considerable CAGR across the
analysis period 2019 to 2025. By 2025, the meningococcal vaccine market can
touch USD Million from USD 172 Million in 2019.
Get Sample Report- https://www.marketresearchfuture.com/sample_request/8622
The rise in cases of
meningococcal disease is expected to support the expansion of the market
through the analysis period. As the mortality rate of meningococcal disease
surge, the demand for vaccine increases. A high number of people have shown
resistance to the disorder on vaccination. Thus, the increase in cases of
prevention of meningococcal disorder by vaccination have created high demand.
The rise in the production for meningococcal vaccine is observed to meet its
rising need. These factors are expected to drive the market across the analysis
period. In addition, hefty investment and increase in research and development
for the identification and formulation of novel drug moiety to prevent
meningococcal vaccine market can bolster the rise of the market through the
review period. However, issues regarding approval of research projects can
limit the growth of the meningococcal vaccine market in the years ahead.
Key Players
Baxter International, Novartis
Pharmaceuticals Canada Inc, Pfizer Inc., Sanofi S.A., Biomed Pvt. Ltd., JN-International
Medical Corporation, GlaxoSmithKline, and Serum Institute of India Ltd. among
others are some influential meningococcal vaccines markets as listed by MRFR.
Market Segmentation
The segment assessment of the Meningococcal
Vaccines global Market is done by treatment type and end-user.
·
The treatment type based segments of the
meningococcal market are polysaccharide, sub-capsular vaccine, and
meningococcal conjugate vaccine. The polysaccharide segment can surge due to
the increase in demand for products, such as MenACWY vaccines. In addition, the
rise in demand for novel MenB vaccines can support the expansion of the
meningococcal vaccine market across the analysis period.
·
The end-user based segments of the meningococcal
vaccines global market are research & academic institutes, and hospitals
& clinics among others. The hospitals and clinics segment is expected to significantly
control the meningococcal vaccines market in the years to come. The expansion
of the hospitals and clinics segment can be attributed to the rise in the application
of vaccines and easy accessibility to healthcare facilities. The rise in number
of in-patients suffering from meningococcal disease can contribute to the
expansion of the segment, which, in turn, impact the market rise. The increase
in R&D for the investigation of new drug to treat meningococcal problem can
cause the research laboratories and academic segment to surge in the years to
come.
Regional Analysis
The application of meningococcal
vaccines for the immunization of special risk groups, such as travellers and
military personnel are highly recommended, although not-reimbursed. The launch
of immunization program in meningitis prone countries include meningococcal
vaccines only for risk groups. The increased in such cases and active steps
taken by healthcare welfare controlling governments and organizations are
forces that are likely to contribute to the expansion of the meningococcal
vaccines market in the Asia Pacific region. The rise in interest for the introduction
of multivalent and conjugate vaccine into scheduled national immunization
programs in the MEA region can contribute to the regional market expansion. In
North America, the easy availability of expertise can contribute to the
expansion of the regional market. The ease of availability of C- and
W-containing vaccines as issues related to these sero-groups are increasing can
support the expansion of meningococcal market across the analysis period.
Europe meningococcal vaccine market can surge due to the increase in cases of
medical cases in the region.
Industry
News
·
November 2020
A renowned French pharma company, Sanofi, has
received approval from the European Commission for its Meningococcal (MenACWY)
vaccine MenQuadfi. The EC has given conformity for immunizing the individuals
from the age of 12 months and older.
Browse Full Report-
https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622
Related Report-
Hearing Aids Market Research Report - Global Forecast till 2027
Patient Engagement Solutions Market Research Report - Global Forecast
till 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment